Verition Fund Management
AVIR icon

Verition Fund Management’s Atea Pharmaceuticals AVIR Stock Holding History

Verition Fund Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-67,304
Closed -$225K – 3324
2024
Q4 		$225K Buy
67,304
+10,395
+18% +$34.5K ﹤0.01% 2929
2024
Q3 		$191K Sell
56,909
-9,067
-14% -$32.9K ﹤0.01% 2897
2024
Q2 		$218K Buy
+65,976
New +$246K ﹤0.01% 2541
2023
Q4 		– Sell
-22,954
Closed -$68.9K – 2339
2023
Q3 		$68.9K Buy
+22,954
New +$78.1K ﹤0.01% 2154
2021
Q3 		– Sell
-14,375
Closed -$309K – 1892
2021
Q2 		$309K Buy
+14,375
New +$432K ﹤0.01% 1332

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Verition Fund Management's AVIR Position: Q1 2025 in Review

Verition Fund Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2025, closing a stake of 67,304 shares — an estimated $225K sold.

Verition Fund Management first reported a position in AVIR in Q2 2021 and held it in 5 quarters. The position peaked at $309K in Q2 2021. 103 funds tracked by Wall St. Rank hold AVIR as of Q1 2025.

  • Verition Fund Management reported no remaining Atea Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 67,304 Atea Pharmaceuticals shares in Q1 2025, an estimated $225K.
  • Verition Fund Management first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Verition Fund Management's Atea Pharmaceuticals position peaked at $309K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.